nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefpodoxime—Body temperature increased—Teniposide—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Cefpodoxime—Paraesthesia—Fludarabine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Cefpodoxime—Hallucination—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Cefpodoxime—Dyspnoea—Fludarabine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Cefpodoxime—Haematuria—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cefpodoxime—Oedema peripheral—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cefpodoxime—Dyspepsia—Fludarabine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Cefpodoxime—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Cefpodoxime—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Cefpodoxime—Decreased appetite—Fludarabine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Cefpodoxime—Fatigue—Fludarabine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Cefpodoxime—Hallucination—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefpodoxime—Constipation—Fludarabine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefpodoxime—Pain—Fludarabine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefpodoxime—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Cefpodoxime—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefpodoxime—Hypersensitivity—Teniposide—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefpodoxime—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefpodoxime—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Cefpodoxime—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Cefpodoxime—Anaemia—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Cefpodoxime—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Cefpodoxime—Asthenia—Teniposide—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Cefpodoxime—Malaise—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Cefpodoxime—Pruritus—Teniposide—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Cefpodoxime—Leukopenia—Bleomycin—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Cefpodoxime—Alopecia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Cefpodoxime—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Cefpodoxime—Body temperature increased—Fludarabine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Cefpodoxime—Vaginal infection—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Cefpodoxime—Cough—Bleomycin—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Cefpodoxime—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Cefpodoxime—Diarrhoea—Teniposide—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Cefpodoxime—Chest pain—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Cefpodoxime—Myalgia—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Cefpodoxime—Alopecia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Cefpodoxime—Back pain—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Cefpodoxime—Discomfort—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cefpodoxime—Chills—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Cefpodoxime—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Cefpodoxime—Alopecia—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Cefpodoxime—Confusional state—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Cefpodoxime—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Cefpodoxime—Tremor—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Cefpodoxime—Anaemia—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cefpodoxime—Back pain—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cefpodoxime—Vomiting—Teniposide—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Cefpodoxime—Agitation—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Cefpodoxime—Asthenia—Fludarabine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Cefpodoxime—Rash—Teniposide—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Cefpodoxime—Dermatitis—Teniposide—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cefpodoxime—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cefpodoxime—Headache—Teniposide—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Cefpodoxime—Pruritus—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Cefpodoxime—Back pain—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Cefpodoxime—Leukopenia—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Cefpodoxime—Anorexia—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Cefpodoxime—Anaemia—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Cefpodoxime—Agitation—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Cefpodoxime—Hypotension—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Cefpodoxime—Diarrhoea—Fludarabine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Cefpodoxime—Convulsion—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefpodoxime—Hypertension—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefpodoxime—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefpodoxime—Nausea—Teniposide—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Cefpodoxime—Anaemia—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Cefpodoxime—Vertigo—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Cefpodoxime—Leukopenia—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cefpodoxime—Chest pain—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Cefpodoxime—Myalgia—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Cefpodoxime—Anxiety—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Cefpodoxime—Paraesthesia—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Cefpodoxime—Malaise—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Cefpodoxime—Dyspnoea—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Cefpodoxime—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Cefpodoxime—Convulsion—Vincristine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Cefpodoxime—Hypertension—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefpodoxime—Confusional state—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefpodoxime—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Cefpodoxime—Decreased appetite—Bleomycin—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Cefpodoxime—Myalgia—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Cefpodoxime—Cough—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Cefpodoxime—Vomiting—Fludarabine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Cefpodoxime—Convulsion—Mitoxantrone—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Cefpodoxime—Rash—Fludarabine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Cefpodoxime—Dermatitis—Fludarabine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Cefpodoxime—Hypertension—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Cefpodoxime—Pain—Bleomycin—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Cefpodoxime—Headache—Fludarabine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Cefpodoxime—Chest pain—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Cefpodoxime—Myalgia—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Cefpodoxime—Anxiety—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Cefpodoxime—Discomfort—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefpodoxime—Anorexia—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Cefpodoxime—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Cefpodoxime—Confusional state—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefpodoxime—Hypotension—Carmustine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Cefpodoxime—Nausea—Fludarabine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Cefpodoxime—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Cefpodoxime—Shock—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefpodoxime—Urticaria—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefpodoxime—Anorexia—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Cefpodoxime—Body temperature increased—Bleomycin—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Cefpodoxime—Insomnia—Carmustine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Cefpodoxime—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Cefpodoxime—Paraesthesia—Carmustine—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Cefpodoxime—Hypotension—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Cefpodoxime—Dyspnoea—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Cefpodoxime—Somnolence—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Cefpodoxime—Anorexia—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefpodoxime—Decreased appetite—Carmustine—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefpodoxime—Hypotension—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefpodoxime—Insomnia—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefpodoxime—Paraesthesia—Vincristine—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefpodoxime—Pain—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Cefpodoxime—Constipation—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Cefpodoxime—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Cefpodoxime—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Cefpodoxime—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Cefpodoxime—Decreased appetite—Vincristine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Cefpodoxime—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Cefpodoxime—Somnolence—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Cefpodoxime—Feeling abnormal—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Cefpodoxime—Fatigue—Vincristine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Cefpodoxime—Asthenia—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Cefpodoxime—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefpodoxime—Pain—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefpodoxime—Constipation—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefpodoxime—Asthma—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Cefpodoxime—Pruritus—Bleomycin—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Cefpodoxime—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Cefpodoxime—Eosinophilia—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Cefpodoxime—Fatigue—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Cefpodoxime—Pain—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cefpodoxime—Constipation—Mitoxantrone—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cefpodoxime—Body temperature increased—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Cefpodoxime—Abdominal pain—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Cefpodoxime—Pancytopenia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Cefpodoxime—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Cefpodoxime—Dysuria—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Cefpodoxime—Neutropenia—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Cefpodoxime—Abdominal pain—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Cefpodoxime—Body temperature increased—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Cefpodoxime—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Cefpodoxime—Urticaria—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Cefpodoxime—Hypersensitivity—Carmustine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Cefpodoxime—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Cefpodoxime—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Cefpodoxime—Pneumonia—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Cefpodoxime—Vomiting—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Cefpodoxime—Rash—Bleomycin—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Cefpodoxime—Dermatitis—Bleomycin—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Cefpodoxime—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Cefpodoxime—Asthenia—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Cefpodoxime—Renal failure—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Cefpodoxime—Stomatitis—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefpodoxime—Hypersensitivity—Vincristine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefpodoxime—Haematuria—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Cefpodoxime—Epistaxis—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Cefpodoxime—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Cefpodoxime—Asthenia—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Cefpodoxime—Diarrhoea—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Cefpodoxime—Nausea—Bleomycin—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Cefpodoxime—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Cefpodoxime—Asthenia—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Cefpodoxime—Dizziness—Carmustine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Cefpodoxime—Haemoglobin—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Cefpodoxime—Diarrhoea—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Cefpodoxime—Haemorrhage—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Cefpodoxime—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Cefpodoxime—Vomiting—Carmustine—lymphatic system cancer	0.00099	0.00099	CcSEcCtD
Cefpodoxime—Dizziness—Vincristine—lymphatic system cancer	0.000983	0.000983	CcSEcCtD
Cefpodoxime—Rash—Carmustine—lymphatic system cancer	0.000982	0.000982	CcSEcCtD
Cefpodoxime—Dermatitis—Carmustine—lymphatic system cancer	0.000981	0.000981	CcSEcCtD
Cefpodoxime—Headache—Carmustine—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Cefpodoxime—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00096	0.00096	CcSEcCtD
Cefpodoxime—Tinnitus—Methotrexate—lymphatic system cancer	0.000947	0.000947	CcSEcCtD
Cefpodoxime—Vomiting—Vincristine—lymphatic system cancer	0.000945	0.000945	CcSEcCtD
Cefpodoxime—Rash—Vincristine—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Cefpodoxime—Dermatitis—Vincristine—lymphatic system cancer	0.000937	0.000937	CcSEcCtD
Cefpodoxime—Headache—Vincristine—lymphatic system cancer	0.000931	0.000931	CcSEcCtD
Cefpodoxime—Nausea—Carmustine—lymphatic system cancer	0.000925	0.000925	CcSEcCtD
Cefpodoxime—Vomiting—Mitoxantrone—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Cefpodoxime—Rash—Mitoxantrone—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Cefpodoxime—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000912	0.000912	CcSEcCtD
Cefpodoxime—Chills—Methotrexate—lymphatic system cancer	0.000911	0.000911	CcSEcCtD
Cefpodoxime—Headache—Mitoxantrone—lymphatic system cancer	0.000907	0.000907	CcSEcCtD
Cefpodoxime—Alopecia—Methotrexate—lymphatic system cancer	0.000897	0.000897	CcSEcCtD
Cefpodoxime—Nausea—Vincristine—lymphatic system cancer	0.000883	0.000883	CcSEcCtD
Cefpodoxime—Dysgeusia—Methotrexate—lymphatic system cancer	0.000866	0.000866	CcSEcCtD
Cefpodoxime—Nausea—Mitoxantrone—lymphatic system cancer	0.00086	0.00086	CcSEcCtD
Cefpodoxime—Back pain—Methotrexate—lymphatic system cancer	0.000855	0.000855	CcSEcCtD
Cefpodoxime—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Cefpodoxime—Anaemia—Methotrexate—lymphatic system cancer	0.000817	0.000817	CcSEcCtD
Cefpodoxime—Malaise—Methotrexate—lymphatic system cancer	0.000797	0.000797	CcSEcCtD
Cefpodoxime—Vertigo—Methotrexate—lymphatic system cancer	0.000794	0.000794	CcSEcCtD
Cefpodoxime—Leukopenia—Methotrexate—lymphatic system cancer	0.000791	0.000791	CcSEcCtD
Cefpodoxime—Cough—Methotrexate—lymphatic system cancer	0.000771	0.000771	CcSEcCtD
Cefpodoxime—Convulsion—Methotrexate—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Cefpodoxime—Myalgia—Methotrexate—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Cefpodoxime—Chest pain—Methotrexate—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Cefpodoxime—Discomfort—Methotrexate—lymphatic system cancer	0.000744	0.000744	CcSEcCtD
Cefpodoxime—Confusional state—Methotrexate—lymphatic system cancer	0.000727	0.000727	CcSEcCtD
Cefpodoxime—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Cefpodoxime—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Cefpodoxime—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000697	0.000697	CcSEcCtD
Cefpodoxime—Anorexia—Methotrexate—lymphatic system cancer	0.000688	0.000688	CcSEcCtD
Cefpodoxime—Hypotension—Methotrexate—lymphatic system cancer	0.000674	0.000674	CcSEcCtD
Cefpodoxime—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Cefpodoxime—Insomnia—Methotrexate—lymphatic system cancer	0.000653	0.000653	CcSEcCtD
Cefpodoxime—Paraesthesia—Methotrexate—lymphatic system cancer	0.000648	0.000648	CcSEcCtD
Cefpodoxime—Dyspnoea—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Cefpodoxime—Somnolence—Methotrexate—lymphatic system cancer	0.000641	0.000641	CcSEcCtD
Cefpodoxime—Dyspepsia—Methotrexate—lymphatic system cancer	0.000635	0.000635	CcSEcCtD
Cefpodoxime—Decreased appetite—Methotrexate—lymphatic system cancer	0.000627	0.000627	CcSEcCtD
Cefpodoxime—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000623	0.000623	CcSEcCtD
Cefpodoxime—Fatigue—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Cefpodoxime—Pain—Methotrexate—lymphatic system cancer	0.000617	0.000617	CcSEcCtD
Cefpodoxime—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000595	0.000595	CcSEcCtD
Cefpodoxime—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00059	0.00059	CcSEcCtD
Cefpodoxime—Urticaria—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Cefpodoxime—Body temperature increased—Methotrexate—lymphatic system cancer	0.00057	0.00057	CcSEcCtD
Cefpodoxime—Abdominal pain—Methotrexate—lymphatic system cancer	0.00057	0.00057	CcSEcCtD
Cefpodoxime—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000532	0.000532	CcSEcCtD
Cefpodoxime—Asthenia—Methotrexate—lymphatic system cancer	0.000518	0.000518	CcSEcCtD
Cefpodoxime—Pruritus—Methotrexate—lymphatic system cancer	0.00051	0.00051	CcSEcCtD
Cefpodoxime—Diarrhoea—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Cefpodoxime—Dizziness—Methotrexate—lymphatic system cancer	0.000477	0.000477	CcSEcCtD
Cefpodoxime—Vomiting—Methotrexate—lymphatic system cancer	0.000459	0.000459	CcSEcCtD
Cefpodoxime—Rash—Methotrexate—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Cefpodoxime—Dermatitis—Methotrexate—lymphatic system cancer	0.000454	0.000454	CcSEcCtD
Cefpodoxime—Headache—Methotrexate—lymphatic system cancer	0.000452	0.000452	CcSEcCtD
Cefpodoxime—Nausea—Methotrexate—lymphatic system cancer	0.000429	0.000429	CcSEcCtD
